(2R,3S)-3-(4-Methoxy-phenyl)-oxirane-2-carboxylic acid | 128232-06-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: (2R,3S)-3-(4-Methoxy-phenyl)-oxirane-2-carboxylic acid
• 英文别名: trans-(2r,3s)-3-(4-Methoxyphenyl)glycidic acid；(2R,3S)-3-(4-methoxyphenyl)oxirane-2-carboxylic acid
• CAS: 128232-06-4
• 化学式: C₁₀H₁₀O₄
• 分子量: 194.187
• InChiKey: CUHUYVNPCQYRLG-DTWKUNHWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  59.1
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  4-甲氧基苯甲醛 、 氯乙酸甲酯 生成 (2R,3S)-rel-3-(4-甲氧基苯基)-2-环氧乙烷羧酸甲酯 、 (2R,3S)-3-(4-Methoxy-phenyl)-oxirane-2-carboxylic acid
  参考文献：
  名称：

  An Asymmetric Synthesis of PPAR-? Agonist Navaglitazar from (+)-Methyl (2S,3R)-3-(4-methoxyphenyl)glycidate

  摘要：

  这段文字的中文翻译如下：

  描述了一种从商业上可获得的(+)-甲基(2S,3R)-3-(4-甲氧基苯基)环氧乙酸酯合成纳瓦格利塞的不对称合成方法，纳瓦格利塞是一种过氧化物酶体增殖物激活受体(PPAR)α激动剂。这种新合成方法具有高总收率、低溶剂使用量、结晶中间体和操作简便的特点。

  DOI：

  10.2533/chimia.2006.580

文献信息

• Novel 8-chloro-1,5-benzothiazepine derivatives, processes for preparing the same and pharmaceutical compositions
  申请人：Tanabe Seiyaku Co., Ltd.

  公开号：EP0127882A1

  公开（公告）日：1984-12-12

  Novel 8-chloro-1,5-benzothiazepine derivatives of the formula: wherein R' is hydrogen, lower alkyl or a group of the formula: R4CO-, each of R2 and R' is lower alkyl and R4 is hydrogen or lower alkyl, and a pharmaceutically acceptable acid addition salt thereof as well as a process for preparing the same are disclosed. Said derivative (I) and a pharmaceutically acceptable acid addition salt thereof in form of a pharmaceutical composition are useful as hypotensive agents and/or coronary or cerbral vasodilators.

  式中的新型 8-氯-1,5-苯并硫氮杂卓衍生物： 其中 R' 为氢、低级烷基或式中的基团：R4CO-, R2 和 R' 各为低级烷基，R4 为氢或低级烷基）的新型 8-氯-1,5-苯并硫氮杂卓衍生物及其药学上可接受的酸加成盐以及制备方法已被公开。以药物组合物形式存在的上述衍生物（I）及其药学上可接受的酸加成盐可用作降血压剂和/或冠状动脉或脑血管扩张剂。
• Novel 1,5-benzothiazepine derivatives, processes for preparing the same and pharmaceutical compositions
  申请人：Tanabe Seiyaku Co., Ltd.

  公开号：EP0154838A1

  公开（公告）日：1985-09-18

  Novel 1,5-benzothiazepine derivatives of the formula: wherein R1 is lower alkyl or lower alkoxy, R2 is hydrogen atom or lower alkanoyl, each one of R3 and R4 is lower alkyl, Ring A is a substituted benzene ring of the formula: Ra is lower alkyl, lower alkoxy, lower alkylthio or benzyloxy, each one of Rb and R° is lower alkyl, lower alkoxy or halogen atom, and either one of Rd and Re is fluorine atom and the other one is hydrogen atom, or a pharmaceutically acceptable acid addition salt thereof and processes for their production. In form of pharmaceutical compositions said derivative (I) and its salt are useful as a hypotensive agent and/or a cerebral or coronary vasodilator.

  式中的新型 1，5-苯并硫氮杂卓衍生物： 其中R1为低级烷基或低级烷氧基，R2为氢原子或低级烷酰基，R3和R4各自为低级烷基，环A为式中的取代苯环： Ra为低级烷基、低级烷氧基、低级烷硫基或苄氧基，Rb和R°各自为低级烷基、低级烷氧基或卤原子，Rd和Re中的一个为氟原子，另一个为氢原子，或其药学上可接受的酸加成盐及其生产工艺。在药物组合物中，所述衍生物 (I) 及其盐可用作降血压剂和/或脑或冠状动脉血管扩张剂。
• Novel 1,5-benzothiazepine derivative, processes for preparing the same and pharmaceutical compositions
  申请人：Tanabe Seiyaku Co., Ltd.

  公开号：EP0158340A2

  公开（公告）日：1985-10-16

  Novel 1,5-benzothiazepine derivatives of the formula: wherein R' and R4 are: a) R1 is lower alkyl or lower alkoxy, and R4 is lower alkyl, lower alkoxy, fluorine, benzyloxy, hydroxy or lower alkylthio, or b) R' is lower alkyl, and R4 is hydrogen, or c) R' is hydroxy, and R4 is lower alkyl, fluorine, hydroxy or lower alkylthio; R2 is hydrogen, lower alkanoyl or benzoyl; and R3 is lower alkyl; and a pharmaceutically acceptable acid addition salt thereof are disclosed. In form of pharmaceutical compositions the said derivative (I) and its salt have a potent platelet aggregation-inhibiting activity.

  式中的新型 1，5-苯并硫氮杂卓衍生物： 其中 R' 和 R4 是 a) R1 是低级烷基或低级烷氧基，R4 是低级烷基、低级烷氧基、氟、苄氧基、羟基或低级烷硫基，或 b) R' 是低级烷基，R4 是氢，或 c) R' 是羟基，R4 是低级烷基、氟、羟基或低级烷硫基； R2 是氢、低级烷酰基或苯甲酰基；R3 是低级烷基；及其药学上可接受的酸加成盐。在药物组合物中，上述衍生物（I）及其盐具有强效的血小板聚集抑制活性。
• 2,3-Dihydro-2-phenyl-5-aminoalkyl-naphtho [1,2-b]-1,4-thiazepin-4(5H)-one derivatives
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP0234561A2

  公开（公告）日：1987-09-02

  It has been found that the novel compounds of the formula wherein R, is phenyl substituted with 1 to 3 lower alkoxy groups or 1 to 3 halogens, R2 is hydroxy, lower alkoxv. lower alkanovloxv. lower cvcloalkvlcarbonvloxv. R3 and R, are, independently, lower alkyl, phenyl lower alkyl or, taken together, form a piperidine or pyrrolidine ring, n is 2 to 4 and m is 1 to 2, and pharmaceutically acceptable acid addition salts thereof have activity as calcium channel blockers and, accordingly, are useful as agents for treating ischemia and as agents for lowering blood pressure. They can be prepared by reacting a compound of the formula with a compound of the formula and optionally converting the compound thus obtained to a compound wherein R2 is other than hydroxy.

  发现式中的新型化合物 其中 R 是被 1 至 3 个低级烷氧基或 1 至 3 个卤素取代的苯基，R2 是羟基、低级烷氧基、低级烷烃氧基、低级环烷烃氧基、低级环羰基氧基。 R3和R, 独立地是低级烷基、苯基低级烷基，或共同形成哌啶或吡咯烷环，n为2至4，m为1至2、 及其药学上可接受的酸加成盐具有钙通道阻滞剂的活性，因此可用作治疗缺血和降低血压的药物。它们可以通过将式 与式 并选择性地将由此得到的化合物转化为 R2 为羟基以外的化合物。
• 2,3-Dihydro-2-phenyl-5-aminoalkyl-naphto ¬1,8-bc -1,5-thiazocin-4 (5H)-one derivatives
  申请人：F. Hoffmann-La Roche AG

  公开号：EP0239050A1

  公开（公告）日：1987-09-30

  It has been found that the novel compounds of the formula wherein R1 is phenyl substituted with 1 to 3 lower alkoxy groups or 1 to 3 halogens. R2 is hydroxy or lower alkanoyloxy, R3 and R4 are, independently, lower alkyl or, taken together, form a piperidine or pyrrolidine ring and n is 2 to 4, and pharmaceutically acceptable acid addition salts thereof are active as calcium channel blockers and, accordingly, are useful as agents for treating ischemia and as agents for lowering blood pressure. They can be preparated by reacting a compound of the formula with a compound of the formula and optionally lower alkoxylating the compound obtained.

  发现式中的新型化合物 其中 R1 是被 1 至 3 个低级烷氧基或 1 至 3 个卤素取代的苯基。R2 是羟基或低级烷氧基，R3 和 R4 分别是低级烷基，或共同形成哌啶或吡咯烷环，n 是 2 至 4，其药学上可接受的酸加成盐具有钙通道阻滞剂的活性，因此可用作治疗缺血和降低血压的药物。它们可以通过将式 与式 并对得到的化合物进行低级烷氧基化。